Status: Not yet recruiting
Comparison Of Fenofibrate Vs Phenobarbitone As Adjunct To Phototherapy In Reducing Total Serum Bilirubin In Indirect Hyperbilirubinemia In Neonates
This is a prospective, randomized, open-label controlled trial comparing fenofibrate (10 mg/kg) and phenobarbitone (3 mg/kg) as adjuncts to conventional phototherapy in neonates with unconjugated hyperbilirubinemia. The study aims to compare their effectiveness in reducing total serum bilirubin. Secondary outcomes include duration of phototherapy, length of hospital stay, and treatment-related adverse effects.
Participants needed: 70
Trial details
Phase: Phase 4Age: 24-14Biological sex: AllType: InterventionalSponsor: Rubab FatimaUpdated: Aug 19, 2026
Eligibility criteria
Term neonates aged 24 hours to 14 days with gestational age 37-42 weeks. [+3]
Preterm or low-birth-weight neonates. [+5]